InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases a new version of LikelihoodProfiler.jl. LikelihoodProfiler represents a unified Julia package that can be used for practical identifiability analysis for complex computationally demanding QSP models.
Initially, LikelihoodProfiler.jl included a method (CICO) for estimating confidence intervals (CI) and assessing the practical identifiability of model parameters using the profile likelihood approach. Now LikelihoodProfiler package provides various state-of-the-art methods for profile likelihood analysis, including optimization-based and integration-based profiles, CI endpoints search, and more. These methods are now unified under a new interface, making it easier for users to switch between them. The results of LikelihoodProfiler.jl analysis can be used to further reduce the complexity and eliminate model’s uncertainty by implementing identifiable parametrizations and model reduction techniques.
Ivan Borisov, Senior Software Developer, comments on the new version of LikelihoodProfiler.jl, “This release marks the first version of the revamped package. We plan to introduce additional methods, improve interfaces, enhance documentation, and more to make the package more valuable to the community.”
LikelihoodProfiler package is open-source and freely available on GitHub: https://github.com/insysbio/LikelihoodProfiler.jl
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | September 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
1.
09 Sep 2020 14:59
InSysBio to update its Cytocon DB to version 1.2.6.7
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Sep 2020 14:54
InSysBio to take part in ACoP11
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
1.
23 Sep 2020 10:26
InSysBio announces its collaboration with Genmab
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||
Thank you for your message! We will get back to you shortly.
